loading
前日終値:
$0.2111
開ける:
$0.225
24時間の取引高:
62,076
Relative Volume:
0.23
時価総額:
$47.56M
収益:
$74,000
当期純損益:
$-13.43M
株価収益率:
-0.024
EPS:
-9.4
ネットキャッシュフロー:
$-10.54M
1週間 パフォーマンス:
-1.66%
1か月 パフォーマンス:
-29.50%
6か月 パフォーマンス:
-84.22%
1年 パフォーマンス:
-87.11%
1日の値動き範囲:
Value
$0.211
$0.23
1週間の範囲:
Value
$0.2108
$0.2437
52週間の値動き範囲:
Value
$0.1706
$4.00

Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile

Name
名前
Cyclacel Pharmaceuticals Inc
Name
セクター
Healthcare (1153)
Name
電話
908-517-7330
Name
住所
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Name
職員
12
Name
Twitter
Name
次回の収益日
2024-11-11
Name
最新のSEC提出書
Name
CYCC's Discussions on Twitter

CYCC を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CYCC
Cyclacel Pharmaceuticals Inc
0.2256 47.56M 74,000 -13.43M -10.54M -9.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2022-07-18 再開されました Oppenheimer Outperform
2020-04-27 再開されました ROTH Capital Buy
2018-09-07 開始されました Ladenburg Thalmann Buy
2015-10-16 開始されました H.C. Wainwright Buy
2010-02-04 開始されました Roth Capital Buy
2009-10-28 開始されました Merriman Buy
2008-08-12 開始されました Piper Jaffray Buy
2008-03-12 繰り返されました Cantor Fitzgerald Buy
2008-03-12 繰り返されました Collins Stewart Buy
2008-03-12 繰り返されました Needham & Co Buy
2007-11-27 繰り返されました Cantor Fitzgerald Buy
2007-08-10 繰り返されました Cantor Fitzgerald Buy
2007-06-04 繰り返されました Needham & Co Buy
2007-04-23 開始されました Lazard Capital Buy
2007-04-10 開始されました Cantor Fitzgerald Buy
すべてを表示

Cyclacel Pharmaceuticals Inc (CYCC) 最新ニュース

pulisher
Apr 21, 2025

Cyclacel Pharmaceuticals announces preferred stock dividend By Investing.com - Investing.com Canada

Apr 21, 2025
pulisher
Apr 16, 2025

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World

Apr 16, 2025
pulisher
Apr 08, 2025

StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World

Apr 08, 2025
pulisher
Apr 07, 2025

When (CYCCP) Moves Investors should Listen - news.stocktradersdaily.com

Apr 07, 2025
pulisher
Apr 05, 2025

Cyclacel Pharmaceuticals Inc (CYCC) Q2 2024 Earnings Call Transc - GuruFocus

Apr 05, 2025
pulisher
Apr 05, 2025

Fitters Diversified To Dispose Subsidiary To Nasdaq Listed Pharma Firm - businesstoday.com.my

Apr 05, 2025
pulisher
Apr 04, 2025

Fitters plans to sell full stake in unit to US biotech firm - The Malaysian Reserve

Apr 04, 2025
pulisher
Apr 03, 2025

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update - The Manila Times

Apr 03, 2025
pulisher
Apr 03, 2025

Cyclacel Pharmaceuticals Shifts Focus to Cancer Drug Development - TipRanks

Apr 03, 2025
pulisher
Apr 02, 2025

Cyclacel Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Apr 02, 2025
pulisher
Apr 02, 2025

Cyclacel Pharmaceuticals Appoints New Directors Amid Strategic Shift - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results And Provides Business Update - MarketScreener

Apr 02, 2025
pulisher
Mar 31, 2025

Cyclacel Pharmaceuticals Delays 10-K Filing - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

CYCC stock touches 52-week low at $0.29 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

CYCC stock touches 52-week low at $0.29 amid sharp annual decline - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World

Mar 31, 2025
pulisher
Mar 26, 2025

Cyclacel Pharmaceuticals to offer convertible preferred stock in private placement - MSN

Mar 26, 2025
pulisher
Mar 24, 2025

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering Of Convertible Preferred Stock - Marketscreener.com

Mar 24, 2025
pulisher
Mar 24, 2025

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - The Manila Times

Mar 24, 2025
pulisher
Mar 24, 2025

Cyclacel's Latest $1M Financing Deal Reveals Extended Survival Strategy Through Q3 2025 - Stock Titan

Mar 24, 2025
pulisher
Mar 23, 2025

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World

Mar 23, 2025
pulisher
Mar 17, 2025

Cyclacel Pharmaceuticals’ Change of Control Transaction and Appointment of New Executive Leadership - Global Legal Chronicle

Mar 17, 2025
pulisher
Mar 17, 2025

(CYCCP) Trading Advice - news.stocktradersdaily.com

Mar 17, 2025
pulisher
Mar 16, 2025

Cyclacel Pharmaceuticals (CYCC) Projected to Post Earnings on Tuesday - The AM Reporter

Mar 16, 2025
pulisher
Mar 15, 2025

CYCLACEL PHARMACEUTICALS Earnings Preview: Recent $CYCC Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 15, 2025
pulisher
Mar 15, 2025

StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Cyclacel Pharmaceuticals acquires cancer drug assets By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Cyclacel Pharmaceuticals acquires cancer drug assets - Investing.com

Mar 14, 2025
pulisher
Mar 12, 2025

Cyclacel stock plunges to 52-week low at $0.3 amid market challenges - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Cyclacel stock plunges to 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 11, 2025

Cyclacel Pharmaceuticals (CYCC) to Release Earnings on Tuesday - Defense World

Mar 11, 2025
pulisher
Mar 09, 2025

Cyclacel stock plunges to 52-week low of $0.31 amid market challenges - MSN

Mar 09, 2025
pulisher
Mar 07, 2025

Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Feb 28, 2025

Cyclacel Pharmaceuticals interim CEO David Lazar sells $5.5 million in stock - Investing.com India

Feb 28, 2025
pulisher
Feb 27, 2025

Cyclacel Pharmaceuticals Announces New Leadership and Restructuring - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Cyclacel Pharmaceuticals Says Datuk Dr.Doris Wong Sing Ee Elected As CEO & Executive Director - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Cyclacel Pharmaceuticals Expands Executive Leadership Team - citybiz

Feb 27, 2025
pulisher
Feb 27, 2025

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership - The Manila Times

Feb 27, 2025
pulisher
Feb 27, 2025

Investor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Who Now Controls Cyclacel? New Investor Takes 70% Ownership in $6.3M Leadership Overhaul - StockTitan

Feb 27, 2025
pulisher
Feb 26, 2025

Buffett’s on the Sidelines – Should You Follow? - The Globe and Mail

Feb 26, 2025
pulisher
Feb 24, 2025

Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, on Innovative Targeted Therapies for Advanced - DocWire News

Feb 24, 2025
pulisher
Feb 24, 2025

Cyclacel Pharmaceuticals amends agreement with CEO By Investing.com - Investing.com Australia

Feb 24, 2025

Cyclacel Pharmaceuticals Inc (CYCC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
大文字化:     |  ボリューム (24 時間):